IRADIMED CORPORATION (IRMD) Q2 2025 Earnings Call Transcript

IRADIMED CORPORATION (IRMD) reported a record Q2 2025, with revenue up 14% to $20.4 million and GAAP diluted EPS increasing 18% to $0.45. The company's significant growth catalyst is the recent FDA clearance of its new 3870 MRI IV pump system, a 'seminal event' expected to drive substantial demand through replacement of over 6,200 older units and a higher average selling price. This new product cycle underpins management's raised full-year 2025 revenue guidance to $80-$82.5 million and a projected $100 million revenue run rate by 2026, despite anticipated short-term operational inefficiencies during a facility transition.

Analysis

IRADIMED CORPORATION (IRMD) reported its 16th consecutive quarter of record revenue, with Q2 2025 revenue increasing 14% year-over-year to $20.4 million and GAAP diluted EPS growing 18% to $0.45. Growth was broad-based, led by a 19% increase in MRI IV pump sales and strong domestic performance, which now constitutes 89% of total revenue. The central catalyst for the company's future is the recent FDA clearance of its new 3870 IV pump system, an event the CEO described as "seminal." Management has outlined a clear strategy to leverage this new product to drive a significant replacement cycle, targeting an installed base of over 6,200 U.S. pumps that are more than five years old. The company aims to double its annual domestic pump channel sales by 2026, supported by an anticipated 12% higher average selling price for the new model, which is expected to positively impact the firm's consistent 78% gross margin. This strategy underpins the raised full-year 2025 revenue guidance to $80-$82.5 million and management's projection of achieving a $100 million revenue run rate during 2026. Near-term guidance for Q3 2025 is tempered by expected operational inefficiencies from a new facility transition, and management anticipates a temporary slowdown in new pump bookings in Q1 2026 as the sales force transitions, though a 5-6 month pump backlog is expected to insulate revenue.

Key Decisions for Investors

• The primary investment thesis hinges on the successful commercialization of the new 3870 IV pump and execution of its multi-year replacement cycle strategy, which management projects could nearly double domestic pump device revenue and push the company's overall revenue run rate past $100 million in 2026.
• Monitor the transition from the legacy 3860 pump to the new 3870 model, as management has flagged the potential for weak new pump bookings in Q1 2026, though the current multi-month backlog is expected to sustain revenues through this period.
• Evaluate gross margin performance in Q3 2025 for the guided short-term impact of the facility transition, and track the adoption rate and average selling price uplift of the 3870 pump in early 2026 to validate the company's ambitious growth trajectory.
• Consider the company's strong balance sheet, with $53 million in cash and robust free cash flow, which supports both growth-oriented capital expenditures and a declared quarterly dividend, providing a degree of shareholder return amidst a significant product cycle.